Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.

Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X, Hwang I, Bagadion AM, Sboner A, Elemento O, Paik J, Yu J, Barbieri CE, Dephoure N, Beltran H, Rickman DS.

J Clin Invest. 2019 Jul 1;130:3924-3940. doi: 10.1172/JCI127961.

2.

Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.

Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, Isse K, Kearney M, Vosoughi A, Fernandez L, Pan H, Motanagh S, Hess J, Donoghue AJ, Sboner A, Wang Y, Dittamore R, Rickman D, Nanus DM, Tagawa ST, Elemento O, Mosquera JM, Saunders L, Beltran H.

Sci Transl Med. 2019 Mar 20;11(484). pii: eaav0891. doi: 10.1126/scitranslmed.aav0891.

3.

ONECUT2 is a driver of neuroendocrine prostate cancer.

Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, Xu X, Xu J, Sheahan AV, Ba-Alawi W, Zhang S, Mahamud O, Vellanki RN, Gleave M, Bristow RG, Haibe-Kains B, Poirier JT, Rudin CM, Tsao MS, Wouters BG, Fazli L, Feng FY, Ellis L, van der Kwast T, Berlin A, Koritzinsky M, Boutros PC, Zoubeidi A, Beltran H, Wang Y, He HH.

Nat Commun. 2019 Jan 17;10(1):278. doi: 10.1038/s41467-018-08133-6.

4.

A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J, Mosquera JM, Sailer V, Bareja R, Romanel A, Gumpeni N, Sboner A, Dardenne E, Puca L, Prandi D, Rubin MA, Scher HI, Rickman DS, Demichelis F, Nanus DM, Ballman KV, Tagawa ST.

Clin Cancer Res. 2019 Jan 1;25(1):43-51. doi: 10.1158/1078-0432.CCR-18-1912. Epub 2018 Sep 19.

PMID:
30232224
5.

Patient derived organoids to model rare prostate cancer phenotypes.

Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M, Gao D, Cyrta J, Sailer V, Vosoughi A, Pauli C, Churakova Y, Cheung C, Deonarine LD, McNary TJ, Rosati R, Tagawa ST, Nanus DM, Mosquera JM, Sawyers CL, Chen Y, Inghirami G, Rao RA, Grandori C, Elemento O, Sboner A, Demichelis F, Rubin MA, Beltran H.

Nat Commun. 2018 Jun 19;9(1):2404. doi: 10.1038/s41467-018-04495-z.

6.

Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.

Puca L, Vlachostergios PJ, Beltran H.

Cold Spring Harb Perspect Med. 2019 Feb 1;9(2). pii: a030593. doi: 10.1101/cshperspect.a030593. Review.

PMID:
29844220
7.

Emerging Variants of Castration-Resistant Prostate Cancer.

Vlachostergios PJ, Puca L, Beltran H.

Curr Oncol Rep. 2017 May;19(5):32. doi: 10.1007/s11912-017-0593-6. Review.

8.

Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.

Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R, McNary TJ, Churakova Y, Cheung C, Triscott J, Pisapia D, Rao R, Mosquera JM, Robinson B, Faltas BM, Emerling BE, Gadi VK, Bernard B, Elemento O, Beltran H, Demichelis F, Kemp CJ, Grandori C, Cantley LC, Rubin MA.

Cancer Discov. 2017 May;7(5):462-477. doi: 10.1158/2159-8290.CD-16-1154. Epub 2017 Mar 22.

9.

c-FLIPL enhances anti-apoptotic Akt functions by modulation of Gsk3β activity.

Quintavalle C, Incoronato M, Puca L, Acunzo M, Zanca C, Romano G, Garofalo M, Iaboni M, Croce CM, Condorelli G.

Cell Death Differ. 2017 Jun;24(6):1134. doi: 10.1038/cdd.2017.7. Epub 2017 Jan 20.

10.

N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.

Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, Cyrta J, Sboner A, Noorzad Z, MacDonald T, Cheung C, Yuen KS, Gao D, Chen Y, Eilers M, Mosquera JM, Robinson BD, Elemento O, Rubin MA, Demichelis F, Rickman DS.

Cancer Cell. 2016 Oct 10;30(4):563-577. doi: 10.1016/j.ccell.2016.09.005.

11.

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.

Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV, Varambally S, Tomlins SA, Nanus DM, Tagawa ST, Van Allen EM, Elemento O, Sboner A, Garraway LA, Rubin MA, Demichelis F.

Nat Med. 2016 Mar;22(3):298-305. doi: 10.1038/nm.4045. Epub 2016 Feb 8.

12.

An emerging role for cytopathology in precision oncology.

Pauli C, Puca L, Mosquera JM, Robinson BD, Beltran H, Rubin MA, Rao RA.

Cancer Cytopathol. 2016 Mar;124(3):167-73. doi: 10.1002/cncy.21647. Epub 2015 Dec 7.

13.

Α-arrestins - new players in Notch and GPCR signaling pathways in mammals.

Puca L, Brou C.

J Cell Sci. 2014 Apr 1;127(Pt 7):1359-67. doi: 10.1242/jcs.142539.

14.

Α-arrestin 1 (ARRDC1) and β-arrestins cooperate to mediate Notch degradation in mammals.

Puca L, Chastagner P, Meas-Yedid V, Israël A, Brou C.

J Cell Sci. 2013 Oct 1;126(Pt 19):4457-68. doi: 10.1242/jcs.130500. Epub 2013 Jul 25.

15.

c-FLIPL enhances anti-apoptotic Akt functions by modulation of Gsk3β activity.

Quintavalle C, Incoronato M, Puca L, Acunzo M, Zanca C, Romano G, Garofalo M, Iaboni M, Croce CM, Condorelli G.

Cell Death Differ. 2010 Dec;17(12):1908-16. doi: 10.1038/cdd.2010.65. Epub 2010 May 28. Retraction in: Cell Death Differ. 2017 Jun;24(6):1134.

16.

Akt regulates drug-induced cell death through Bcl-w downregulation.

Garofalo M, Quintavalle C, Zanca C, De Rienzo A, Romano G, Acunzo M, Puca L, Incoronato M, Croce CM, Condorelli G.

PLoS One. 2008;3(12):e4070. doi: 10.1371/journal.pone.0004070. Epub 2008 Dec 30.

Supplemental Content

Support Center